Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

April 30, 2020

Conditions
Myotonic Dystrophy, Type 1 (DM1)Myotonic Dystrophy
Interventions
DRUG

ERX-963

Active medicine

DRUG

Placebo

Comparator

Trial Locations (4)

20815

The Center for Sleep & Wake Disorders, Chevy Chase

33126

Sleep Medicine Specialists of South Florida, Miami

52242

University of Iowa, Iowa City

94305

Stanford Neurosciences Health Center, Palo Alto

Sponsors
All Listed Sponsors
lead

Expansion Therapeutics, Inc.

INDUSTRY